You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 7,998,459

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,998,459

Title:	Pharmaceutical composition of nanoparticles
Abstract:	The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Inventor(s):	Sung; Hsing-Wen (Hsinchu, TW), Tu; Hosheng (Newport Beach, CA)
Assignee:	GP Medical, Inc. (Newport Beach, CA) National Tsing Huu University (Hsinchu, TW)
Application Number:	12/932,971
Patent Claims:	1. A pharmaceutical composition of nanoparticles, said nanoparticles consisting of a shell portion that is dominated by positively charged chitosan, a core portion that consists of said positively charged chitosan, one negatively charged substrate, at least one bioactive agent loaded within said nanoparticles, and optionally a zero-charge compound, wherein said at least one bioactive agent is an anti-hemophilic factor. 2. The pharmaceutical composition of claim 1, wherein said chitosan is N-trimethyl chitosan, EDTA-chitosan, low molecular weight chitosan, mono-N-carboxymethyl chitosan, chitosan derivatives, or combinations thereof. 3. The pharmaceutical composition of claim 1, wherein said nanoparticles are formed via a simple and mild ionic-gelation process. 4. The pharmaceutical composition of claim 1, wherein said nanoparticles are in a tablet or pill configuration. 5. The pharmaceutical composition of claim 4, wherein said tablet or pill is treated with an enteric coating. 6. The pharmaceutical composition of claim 1, wherein said nanoparticles are freeze-dried, thereby said nanoparticles being in a powder form. 7. The pharmaceutical composition of claim 1, wherein said nanoparticles are loaded in a capsule. 8. The pharmaceutical composition of claim 7, wherein said capsule further comprises a pharmaceutically acceptable carrier, diluent, or excipient. 9. The pharmaceutical composition of claim 7, wherein said capsule further comprises at least a solubilizer, bubbling agent, dispersion agent, or emulsifier. 10. The pharmaceutical composition of claim 7, wherein said capsule is treated with an enteric coating. 11. The pharmaceutical composition of claim 7, wherein said capsule further comprises at least one absorption enhancer. 12. The pharmaceutical composition of claim 1, wherein said nanoparticles are treated with an enteric coating. 13. The pharmaceutical composition of claim 12, wherein said absorption enhancer is selected from the group consisting of bile salts, surfactants, medium-chain fatty acids, phosphate esters, chitosan, and chitosan derivatives. 14. The pharmaceutical composition of claim 1, wherein said negatively charged substrate is PGA-complexone conjugate, .gamma.-PGA, .alpha.-PGA, derivatives of PGA, salts of PGA, or combinations thereof. 15. The pharmaceutical composition of claim 1, wherein said zero-charge compound is an absorption enhancer. 16. The pharmaceutical composition of claim 1, wherein said anti-hemophilic factor is a recombinant human coagulation factor VIIa (rFVIIa) or a recombinant plasma/serum-free coagulation factor VIII. 17. The pharmaceutical composition of claim 1, wherein said anti-hemophilic factor is selected from the group consisting of Bioclate (manufactured by Aventis Behring), Helixate (manufactured by CSL Behring), Kogenate (manufactured by Bayer Healthcare), Recombinate (manufactured by Baxter Healthcare) Advate (manufactured by Baxter Healthcare), Alphanate (manufactured by Grifols SA), Hemofil-M (manufactured by Baxter Healthcare), Humate-P (manufactured by CLS Behrng), Koate (manufactured by Talecris Biotherapeutics), Monarc-M (manufactured by Baxter Healthcare), Monoclate-P (manufactured by CSL Behring), and Refacto (manufactured by Wyeth). 18. The pharmaceutical composition of claim 1, wherein said anti-hemophilic factor is a coagulation factor to treat an animal subject that lacks functional clotting factor VIII, factor IX, or factor XI. 19. The pharmaceutical composition of claim 1, wherein said anti-hemophilic factor is covalently attached with polyethylene glycol polymer chains. 20. The pharmaceutical composition of claim 1, wherein said anti-hemophilic factor is a glycoprotein procofactor.

Details for Patent 7,998,459

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	KOATE, KOATE-DVI	antihemophilic factor (human)	For Injection	101130	01/24/1974	⤷ Try a Trial	2025-01-04
Baxalta Us Inc.	HEMOFIL M	antihemophilic factor (human)	For Injection	101448	03/14/2001	⤷ Try a Trial	2025-01-04
Grifols Biologicals Llc	ALPHANATE	antihemophilic factor/von willebrand factor complex (human)	For Injection	102475	08/15/1978	⤷ Try a Trial	2025-01-04
Grifols Biologicals Llc	ALPHANATE	antihemophilic factor/von willebrand factor complex (human)	For Injection	102475	06/26/2014	⤷ Try a Trial	2025-01-04
Baxalta Us Inc.	BIOCLATE (ARMOUR), RECOMBINATE	antihemophilic factor (recombinant)	For Injection	103375	12/10/1992	⤷ Try a Trial	2025-01-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.